Atypical femoral fracture in a bisphosphonate-naïve patient on denosumab for osteoporosis
- PMID: 36180610
- DOI: 10.1007/s11657-022-01166-x
Atypical femoral fracture in a bisphosphonate-naïve patient on denosumab for osteoporosis
Abstract
A post-menopausal Caucasian woman sustained an atypical femoral fracture (AFF) after 5-years continuous denosumab for osteoporosis without prior bisphosphonate exposure. This is only the fifth case reported of AFF in a bisphosphonate-naïve patient receiving denosumab for osteoporosis. Although rare, physicians should consider AFF in patients taking denosumab even without prior bisphosphonate exposure.
Introduction: Denosumab has demonstrated overwhelmingly favourable skeletal benefit/risk profile in managing post-menopausal osteoporosis with up to 10-year exposure in the extension of the pivotal FREEDOM randomised placebo-controlled trial. Four previous cases of atypical femoral fracture have been reported in bisphosphonate-naïve patients receiving denosumab for osteoporosis.
Methods: We present an 85-year-old Caucasian post-menopausal woman without prior fragility fracture who sustained unilateral atypical femoral fracture after 5-years continuous subcutaneous denosumab for osteoporosis. She had no prior bisphosphonate or glucocorticoid exposure and had known chronic kidney disease.
Results: X-ray scan demonstrated complete, non-comminuted left proximal femoral shaft fracture meeting radiographic criteria for an atypical femoral fracture. Computed tomography (CT) scan lower limbs revealed unusual side-by-side appearance of proximal and distal fragments of left proximal femur. DXA BMD was artefactually elevated at lumbar spine (1.504 g/cm2, T-score + 2.5) and low-normal at right femoral neck (0.856 g/cm2, T-score -1.0). Serum biochemistry showed renal impairment at baseline (eGFR 30 mL/min/1.73m2). Low-normal serum C telopeptide of type 1 collagen (CTX) (230 ng/L) indicated therapeutic suppression of bone resorption.
Conclusion: The patient underwent intramedullary nailing of the femur and denosumab was ceased. This is only the fifth case reported of atypical femoral fracture in a bisphosphonate-naïve patient receiving denosumab for osteoporosis. Although rare, physicians should maintain a high index of suspicion for atypical femoral fracture in a patient taking denosumab even without prior bisphosphonate exposure.
Keywords: Atypical femoral fracture; Bisphosphonate; Denosumab; Osteoporosis.
© 2022. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.
Comment in
-
Atypical femoral fracture after denosumab for the treatment of osteoporosis in bisphosphonate naïve patients: two further cases.Osteoporos Int. 2023 Oct;34(10):1807-1808. doi: 10.1007/s00198-023-06869-6. Osteoporos Int. 2023. PMID: 37526671 No abstract available.
References
-
- Black DM, Abrahamsen B, Bouxsein ML et al (2019) Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev 40(2):333–368. https://doi.org/10.1210/er.2018-00001 - DOI - PubMed
-
- Black DM, Rosen CJ (2016) Clinical practice: postmenopausal osteoporosis. N Engl J Med 374(3):254–262. https://doi.org/10.1056/NEJMcp1513724 - DOI - PubMed
-
- Shane E, Burr D, Abrahamsen B, Adler RA et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23. https://doi.org/10.1002/jbmr.1998 - DOI - PubMed
-
- Dell RM, Adams AL, Greene DF et al (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27(12):2544–2550. https://doi.org/10.1002/jbmr.1719 - DOI - PubMed
-
- Zhou W, van Rooij JGJ, Ebeling PR et al (2021) The genetics of atypical femur fractures-a systematic review. Curr Osteoporos Rep 19(2):123–130. https://doi.org/10.1007/s11914-021-00658-y - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
